Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minimally Invasive Spine Technique Gets Second Look By CMS

This article was originally published in The Gray Sheet

Executive Summary

The Medicare agency is reconsidering coverage of percutaneous image-guided lumbar decompression for lumbar spine stenosis in response to a request by device manufacturer Vertos. The firm's goal is to lift current clinical trial conditions for coverage of the procedure.

You may also be interested in...



Medicare Slightly Expands Coverage For Spine Procedure, But Policy Remains Trial-Limited

Vertos Medical asked the US Medicare agency to reconsider its 2014 decision that limits coverage of percutaneous image-guided lumbar decompression for lumbar spine stenosis to certain clinical trials. The agency ruled Dec. 7 that it will stick with the trial-limited policy, but expanded it to include longitudinal studies.

Spine Firms Laud CMS’ Decision To Cover Percutaneous Lumbar Decompression In Trials

Spinal device makers, who objected to CMS’ proposal for outright noncoverage of percutaneous image-guided lumbar decompression, are pleased with the agency’s final decision to cover PILD when provided in a clinical study through coverage with evidence development.

Device Makers Want Say In Medicare 'Coverage-With-Evidence-Development' Policy

Manufacturers seek more input on trial designs and objectives when CMS takes the "coverage-with-evidence-development" route to national Medicare coverage.

Related Content

Related Companies

UsernamePublicRestriction

Register

MT034685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel